PL2196475T3 - Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie - Google Patents
Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanieInfo
- Publication number
- PL2196475T3 PL2196475T3 PL07800860T PL07800860T PL2196475T3 PL 2196475 T3 PL2196475 T3 PL 2196475T3 PL 07800860 T PL07800860 T PL 07800860T PL 07800860 T PL07800860 T PL 07800860T PL 2196475 T3 PL2196475 T3 PL 2196475T3
- Authority
- PL
- Poland
- Prior art keywords
- modified
- application
- polyethylene glycol
- synthesis process
- interferon alpha
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title 1
- 108010047761 Interferon-alpha Proteins 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07800860A EP2196475B1 (en) | 2007-09-04 | 2007-09-04 | INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| PCT/CN2007/002643 WO2009030065A1 (zh) | 2007-09-04 | 2007-09-04 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2196475T3 true PL2196475T3 (pl) | 2012-10-31 |
Family
ID=40428421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07800860T PL2196475T3 (pl) | 2007-09-04 | 2007-09-04 | Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8597634B2 (pl) |
| EP (1) | EP2196475B1 (pl) |
| KR (1) | KR101483814B1 (pl) |
| CN (1) | CN101636411B (pl) |
| BR (1) | BRPI0721988B1 (pl) |
| CA (1) | CA2698396C (pl) |
| DK (1) | DK2196475T3 (pl) |
| ES (1) | ES2386575T3 (pl) |
| PL (1) | PL2196475T3 (pl) |
| PT (1) | PT2196475E (pl) |
| WO (1) | WO2009030065A1 (pl) |
| ZA (1) | ZA201001555B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| EP2186830B1 (en) * | 2007-09-04 | 2012-03-07 | Biosteed Gene Expression Tech. CO., LTD. | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| PT2196475E (pt) | 2007-09-04 | 2012-09-07 | Biosteed Gene Expression Tech Co Ltd | Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação |
| CA2847837A1 (en) | 2011-09-05 | 2013-03-14 | Hanmi Science Co., Ltd. | A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
| US11559567B2 (en) | 2014-11-06 | 2023-01-24 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| CN106924754B (zh) * | 2015-12-30 | 2021-11-09 | 北京大学 | 聚氨基酸偶联物 |
| CN116120424A (zh) * | 2022-06-06 | 2023-05-16 | 江苏靶标生物医药研究所有限公司 | 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| CN1243779A (zh) | 1998-07-31 | 2000-02-09 | 东莞中镇鞋材有限公司 | 纤维板及其制造方法 |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| ES2291620T3 (es) * | 2002-03-13 | 2008-03-01 | Beijing Jiankai Technology Co., Ltd. | Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior. |
| US20060223145A1 (en) * | 2002-11-01 | 2006-10-05 | Lohray Braj B | Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
| MXPA05005178A (es) * | 2002-11-15 | 2005-07-22 | Hoffmann La Roche | Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). |
| EP2186830B1 (en) | 2007-09-04 | 2012-03-07 | Biosteed Gene Expression Tech. CO., LTD. | Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| PT2196475E (pt) | 2007-09-04 | 2012-09-07 | Biosteed Gene Expression Tech Co Ltd | Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação |
-
2007
- 2007-09-04 PT PT07800860T patent/PT2196475E/pt unknown
- 2007-09-04 CA CA2698396A patent/CA2698396C/en active Active
- 2007-09-04 BR BRPI0721988-1A patent/BRPI0721988B1/pt active IP Right Grant
- 2007-09-04 WO PCT/CN2007/002643 patent/WO2009030065A1/zh not_active Ceased
- 2007-09-04 EP EP07800860A patent/EP2196475B1/en active Active
- 2007-09-04 KR KR1020107007268A patent/KR101483814B1/ko active Active
- 2007-09-04 PL PL07800860T patent/PL2196475T3/pl unknown
- 2007-09-04 DK DK07800860.4T patent/DK2196475T3/da active
- 2007-09-04 CN CN2007800505413A patent/CN101636411B/zh active Active
- 2007-09-04 US US12/676,511 patent/US8597634B2/en active Active
- 2007-09-04 ES ES07800860T patent/ES2386575T3/es active Active
-
2010
- 2010-03-03 ZA ZA2010/01555A patent/ZA201001555B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009030065A1 (zh) | 2009-03-12 |
| EP2196475B1 (en) | 2012-06-06 |
| WO2009030065A8 (zh) | 2009-09-11 |
| EP2196475A4 (en) | 2010-10-20 |
| CN101636411A (zh) | 2010-01-27 |
| US8597634B2 (en) | 2013-12-03 |
| ES2386575T3 (es) | 2012-08-23 |
| PT2196475E (pt) | 2012-09-07 |
| KR20100063108A (ko) | 2010-06-10 |
| KR101483814B1 (ko) | 2015-01-16 |
| US20100239532A1 (en) | 2010-09-23 |
| BRPI0721988A2 (pt) | 2016-10-18 |
| DK2196475T3 (da) | 2012-09-17 |
| EP2196475A1 (en) | 2010-06-16 |
| CA2698396C (en) | 2014-01-21 |
| CN101636411B (zh) | 2013-01-09 |
| ZA201001555B (en) | 2010-11-24 |
| BRPI0721988B1 (pt) | 2021-07-27 |
| CA2698396A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252561A0 (en) | Antibodies against Siglac-15 polynucleotides encoding them, preparations containing them and their uses | |
| IL241633A0 (en) | History of benzodiazepines, preparations containing them and their uses | |
| ZA201002773B (en) | Porcine dc-sign,icam-3 and lsectin and uses thereof | |
| IL216254A (en) | Compounds, pharmaceutical compositions and their uses | |
| EP2173732A4 (en) | PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC | |
| EP2223969A4 (en) | RESIN COMPOSITION, TRANSPARENT ELEMENT DERIVED FROM THE RESIN COMPOSITION AND USE | |
| IL201891A0 (en) | Novel pharmaceutical composition | |
| IL220283A0 (en) | 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof | |
| IL215661A (en) | Preserved phenylureas and phenylamides and pharmaceutical preparations containing them | |
| SI2497801T1 (sl) | Na polifenilen-etru osnovan smolni sestavek in ulitki, ki ga uporabljajo | |
| EP2172521A4 (en) | POLYCARBONATE RESIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME | |
| GB0715383D0 (en) | Interferon | |
| ZA201001555B (en) | Interferon alpha 2a modified by polyethylene glycol,its synthesis process and application | |
| EG26893A (en) | Nanometric-sized ceramic materials, process for their synthesis and uses thereof | |
| GB0706077D0 (en) | Methods, Compositions and uses thereof | |
| EP2142350A4 (en) | METAL ADHESION MOLDING PROCESS AND PRODUCT OBTAINED USING THE SAME | |
| EP2177565A4 (en) | RESIN COMPOSITION AND RESIN PRODUCT | |
| IL188896A0 (en) | Diazepinoquinolines, synthesis thereof, and intermediates thereto | |
| GB2458080B (en) | Sterols modified by polyethylene glycol, the preparation and the use thereof | |
| AP2010005388A0 (en) | Pupicidal and larvicidal composition. | |
| ZA201006443B (en) | Novel immunoregularory peptides,compositions and uses thereof | |
| IL207174A0 (en) | Peptides, compositions, and uses thereof | |
| GB0712903D0 (en) | Novel redox catalyst and its uses | |
| GB0606033D0 (en) | Plant Promoters, Coding Sequence And Their Uses | |
| IL195226A0 (en) | Oxindoledioxans, synthesis thereof, and intermediates thereto |